279 related articles for article (PubMed ID: 18240972)
1. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation.
Léger B; Derave W; De Bock K; Hespel P; Russell AP
Rejuvenation Res; 2008 Feb; 11(1):163-175B. PubMed ID: 18240972
[TBL] [Abstract][Full Text] [Related]
2. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients.
Léger B; Senese R; Al-Khodairy AW; Dériaz O; Gobelet C; Giacobino JP; Russell AP
Muscle Nerve; 2009 Jul; 40(1):69-78. PubMed ID: 19533653
[TBL] [Abstract][Full Text] [Related]
3. Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy.
Haddad F; Adams GR
J Appl Physiol (1985); 2006 Apr; 100(4):1188-203. PubMed ID: 16373446
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass.
Frost RA; Lang CH
J Appl Physiol (1985); 2007 Jul; 103(1):378-87. PubMed ID: 17332274
[TBL] [Abstract][Full Text] [Related]
5. Effects of 3 days unloading on molecular regulators of muscle size in humans.
Gustafsson T; Osterlund T; Flanagan JN; von Waldén F; Trappe TA; Linnehan RM; Tesch PA
J Appl Physiol (1985); 2010 Sep; 109(3):721-7. PubMed ID: 20538844
[TBL] [Abstract][Full Text] [Related]
6. Mice overexpressing growth hormone exhibit increased skeletal muscle myostatin and MuRF1 with attenuation of muscle mass.
Consitt LA; Saneda A; Saxena G; List EO; Kopchick JJ
Skelet Muscle; 2017 Sep; 7(1):17. PubMed ID: 28870245
[TBL] [Abstract][Full Text] [Related]
7. Prolonged absence of myostatin reduces sarcopenia.
Siriett V; Platt L; Salerno MS; Ling N; Kambadur R; Sharma M
J Cell Physiol; 2006 Dec; 209(3):866-73. PubMed ID: 16972257
[TBL] [Abstract][Full Text] [Related]
8. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease.
Doucet M; Russell AP; Léger B; Debigaré R; Joanisse DR; Caron MA; LeBlanc P; Maltais F
Am J Respir Crit Care Med; 2007 Aug; 176(3):261-9. PubMed ID: 17478621
[TBL] [Abstract][Full Text] [Related]
9. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus.
Jørgensen JO; Jessen N; Pedersen SB; Vestergaard E; Gormsen L; Lund SA; Billestrup N
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E899-905. PubMed ID: 16757551
[TBL] [Abstract][Full Text] [Related]
10. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.
Léger B; Cartoni R; Praz M; Lamon S; Dériaz O; Crettenand A; Gobelet C; Rohmer P; Konzelmann M; Luthi F; Russell AP
J Physiol; 2006 Nov; 576(Pt 3):923-33. PubMed ID: 16916907
[TBL] [Abstract][Full Text] [Related]
11. The adaptive responses in several mediators linked with hypertrophy and atrophy of skeletal muscle after lower limb unloading in humans.
Sakuma K; Watanabe K; Hotta N; Koike T; Ishida K; Katayama K; Akima H
Acta Physiol (Oxf); 2009 Oct; 197(2):151-9. PubMed ID: 19432591
[TBL] [Abstract][Full Text] [Related]
12. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy.
Gilson H; Schakman O; Combaret L; Lause P; Grobet L; Attaix D; Ketelslegers JM; Thissen JP
Endocrinology; 2007 Jan; 148(1):452-60. PubMed ID: 17038559
[TBL] [Abstract][Full Text] [Related]
13. Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy.
Wójcik S; Nogalska A; Engel WK; Askanas V
Folia Morphol (Warsz); 2008 Feb; 67(1):6-12. PubMed ID: 18335407
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients.
Wang H; Casaburi R; Taylor WE; Aboellail H; Storer TW; Kopple JD
Kidney Int; 2005 Jul; 68(1):352-61. PubMed ID: 15954927
[TBL] [Abstract][Full Text] [Related]
15. Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway.
Dreyer HC; Glynn EL; Lujan HL; Fry CS; DiCarlo SE; Rasmussen BB
J Appl Physiol (1985); 2008 Jan; 104(1):27-33. PubMed ID: 17885021
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathways weigh in on decisions to make or break skeletal muscle.
Guttridge DC
Curr Opin Clin Nutr Metab Care; 2004 Jul; 7(4):443-50. PubMed ID: 15192448
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease.
Verzola D; Procopio V; Sofia A; Villaggio B; Tarroni A; Bonanni A; Mannucci I; De Cian F; Gianetta E; Saffioti S; Garibotto G
Kidney Int; 2011 Apr; 79(7):773-82. PubMed ID: 21228768
[TBL] [Abstract][Full Text] [Related]
18. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced skeletal muscle atrophy.
Schakman O; Kalista S; Barbé C; Loumaye A; Thissen JP
Int J Biochem Cell Biol; 2013 Oct; 45(10):2163-72. PubMed ID: 23806868
[TBL] [Abstract][Full Text] [Related]
20. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
